Merck KGaA promotes from within new MEA head

pharmafile | October 5, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Merck KGaA, biotech, drugs, pharma, pharmaceutical 

Merck KGaA has installed a new head of its healthcare business for the Middle East, Africa and Turkey (MEA) region, by promoting Paolo Carli from within the company. Carli had previously held the position of Managing Director of the Middle East and Egypt region.

Carli had been working in the previous role for 4 and a half years, after having originally joined Merck as a Director of Corporate Finance, a position he worked in for close to five years focusing upon M&A, and was located in Darmstadt, Germany. Prior to this, he had worked at Deutsche Bank as Vice President of Global Business Development.

Commenting on his appointment Paolo Carli said “Merck prepares to celebrate its 350th year in the pharmaceutical business in 2018. Being a strategic region for Merck, we are committed to excel innovation and create value for patients across this region. I am delighted to lead the MEA team. Our innovative treatment options and sustainable commitment for patients will move us to the next level.”

Advertisement

Carli’s new role will see him responsible for leading commercial operations across MEA.

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …

The Gateway to Local Adoption Series

Latest content